<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment and prognosis of polyarteritis nodosa</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment and prognosis of polyarteritis nodosa</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment and prognosis of polyarteritis nodosa</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A Merkel, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth J Warrington, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that predominantly affects medium-sized muscular arteries and often involves small muscular arteries [<a href="#rid1">1</a>]. The approach to treatment of PAN depends upon the following variables, which require assessment before beginning therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>The level of disease severity</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of isolated cutaneous PAN or other isolated/single-organ disease</p><p class="bulletIndent1"><span class="glyph">●</span>The presence or absence of viral hepatitis</p><p></p><p>The optimal therapy of PAN remains uncertain, and studies of treatment for PAN have been complicated by the mixture of patients with PAN, microscopic polyangiitis (MPA), and sometimes eosinophilic granulomatosis with polyangiitis (Churg-Strauss) within study cohorts [<a href="#rid2">2-4</a>]. The efficacy of glucocorticoids in the majority of patients with mild disease, and of glucocorticoids plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> in patients with more severe disease, has been well demonstrated in observational studies in PAN, but there are few randomized trials [<a href="#rid2">2,3,5-9</a>]. The treatment approach in PAN is also derived from indirect evidence of the efficacy of various medications and drug regiments in other forms of necrotizing vasculitis, particularly MPA and granulomatosis with polyangiitis (GPA). Our approach to therapy is generally consistent with guidelines developed by professional organizations, including the American College of Rheumatology (ACR)/Vasculitis Foundation guideline [<a href="#rid10">10,11</a>].</p><p>The treatment and prognosis of PAN will be reviewed here. The clinical manifestations, diagnosis, and classification of PAN are presented separately (see  <a class="medical medical_review" href="/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a>). The diagnosis and management of cutaneous-only PAN is also discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/109628.html" rel="external">"Cutaneous polyarteritis nodosa"</a>.)</p><p class="headingAnchor" id="H20911895"><span class="h1">PRETREATMENT EVALUATION</span></p><p class="headingAnchor" id="H18234192"><span class="h2">Baseline evaluation</span><span class="headingEndMark"> — </span>Prior to treatment for polyarteritis nodosa (PAN), routine evaluation should include the following (see  <a class="medical medical_review" href="/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical assessment of the extent and severity of organ involvement. The overall goal of the clinical assessment is to determine if the patient has severe or nonsevere disease. PAN may impact multiple organ systems, most commonly the kidneys, nerves, skin, and gastrointestinal tract. Less commonly, PAN can cause digital ischemia.</p><p></p><p class="bulletIndent1">The specific workup is determined by the patient’s symptoms and findings on examination. (See  <a class="medical medical_review" href="/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory assessment for active hepatitis B (ie, hepatitis B surface antigen) or hepatitis C (ie, nucleic acid test for hepatitis C virus [HCV] ribonucleic acid [RNA]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnostic tests, which may include biopsy or angiography of the affected organ. (See  <a class="medical medical_review" href="/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults", section on 'Diagnosis'</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">Minocycline</a> has been suspected of triggering medium-vessel vasculitis and should be stopped [<a href="#rid12">12</a>].</p><p>Consideration should also be given to whether the patient’s presentation may either represent another disease process (eg, deficiency of adenosine deaminase 2 [DADA2] or familial Mediterranean fever) or coexist with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. (See  <a class="medical medical_review" href="/d/html/132472.html" rel="external">"Deficiency of adenosine deaminase 2 (DADA2)"</a> and  <a class="medical medical_review" href="/d/html/122508.html" rel="external">"Autoinflammatory diseases mediated by NFkB and/or aberrant TNF activity", section on 'Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome'</a> and  <a class="medical medical_review" href="/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever"</a>.)</p><p class="headingAnchor" id="H18234207"><span class="h2">Disease extent and severity</span><span class="headingEndMark"> — </span>An important factor in determining which medications will be used and the doses employed is disease extent and severity. We use the following definitions [<a href="#rid3">3,4,7,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe disease</strong> – Patients with severe disease have manifestations that are believed to be organ- or life-threatening (eg, significant kidney disease, mononeuritis multiplex, stroke, myocardial infarction, ischemic bowel). (See <a class="local">'Treatment of severe PAN'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsevere disease</strong> – Patients with nonsevere disease include those without any evidence of severe disease. However, they can have multiple manifestations of PAN, including constitutional symptoms, arthritis, anemia, and skin lesions, or arterial stenoses not causing active ischemia. (See <a class="local">'Treatment of nonsevere PAN'</a> below.)</p><p></p><p class="bulletIndent1">PAN confined to the skin is generally treated similarly to nonsevere systemic PAN. (See  <a class="medical medical_review" href="/d/html/109628.html" rel="external">"Cutaneous polyarteritis nodosa"</a>.)</p><p></p><p>In addition, patients with <strong>isolated or single-organ PAN</strong>, sometimes identified at the time of an operative procedure, may not require further therapy but should be evaluated for evidence of severe or nonsevere disease manifestations. (See <a class="local">'Isolated/single-organ PAN'</a> below.)</p><p class="headingAnchor" id="H2148010"><span class="h1">ASSOCIATED HEPATITIS B OR C INFECTION</span><span class="headingEndMark"> — </span>Patients with both vasculitis and hepatitis virus infection also benefit from treatment with antivirals and plasma exchange. There are no randomized trials or large case series to guide decision-making in such patients; we base our approach upon the available trials in viral hepatitis and clinical experience.</p><p>The treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) and the treatment of kidney disease due to polyarteritis nodosa (PAN) in patients with one of these infections are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3119.html" rel="external">"Kidney disease associated with hepatitis B virus infection", section on 'Polyarteritis nodosa (PAN)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3065.html" rel="external">"Overview of kidney disease associated with hepatitis C virus infection", section on 'Polyarteritis nodosa'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Indications for antiviral therapy'</a>.)</p><p></p><p class="headingAnchor" id="H2270419595"><span class="h2">Role and timing of antiviral therapy</span><span class="headingEndMark"> — </span>In patients in whom PAN is associated with HBV or HCV infection, the major focus of therapy is the use of antiviral agents for treatment of the underlying viral disorder.</p><p>PAN continues to be associated with HBV in a substantial minority of cases, although this rate is decreasing in countries with comprehensive HBV vaccination programs. (See  <a class="medical medical_review" href="/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults", section on 'Etiology'</a>.)</p><p>Far fewer cases of PAN are associated with HCV, which should be differentiated from HCV-associated cryoglobulinemic vasculitis. (See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"</a>.)</p><p>The timing of therapy relative to the use of immunosuppressive agents depends upon the severity of the vasculitis:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with nonsevere PAN and evidence of infection with HBV or HCV, we suggest treating initially with antivirals rather than using immunosuppressive medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients with moderate to severe disease manifestations of hepatitis virus-associated PAN may benefit from short-term treatment with glucocorticoids until antiviral therapy becomes effective [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H3334096709"><span class="h2">Role of immunosuppressive therapy</span><span class="headingEndMark"> — </span>Some patients with PAN associated with viral hepatitis require treatment with the same immunosuppressive regimens employed for patients without viral infections. This group includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with severe disease manifestations (eg, ulcerative or gangrenous lesions of the extremities, acute kidney injury, polyneuropathy, central nervous system involvement, mesenteric arteritis, or myocardial ischemia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with persistent disease manifestations that have had an inadequate response to antiviral therapies</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are intolerant of antiviral therapy</p><p></p><p>The status of the underlying viral infection should be monitored closely in patients who are treated with immunosuppressive agents. Patients also need to be monitored for treatment-associated toxicities, especially hepatic function (which may be impacted by both the viral infection and the treatment regimen). Clinicians managing the immunosuppressive treatment of patients with hepatitis-associated PAN should work closely with experts in the treatment of viral hepatitis.</p><p class="headingAnchor" id="H2414887428"><span class="h2">Role of plasma exchange</span><span class="headingEndMark"> — </span>Given the emergence of more effective therapies for HBV, we do not recommend the routine use of plasma exchange for patients with HBV-associated PAN. We reserve plasma exchange for patients with highly severe and progressive disease for whom use of immunosuppressive therapy is contraindicated.</p><p>There is controversy as to whether patients with hepatitis-associated PAN benefit from plasma exchange. Plasma exchange, typically administered over two to three weeks, removes circulating immune complexes, which may be beneficial in patients with severe disease manifestations. Although the data supporting the use of plasma exchange are weak, immunosuppression and plasma exchange are part of published treatment protocols for HBV-associated PAN [<a href="#rid11">11,14-22</a>].</p><p>A retrospective series treated 80 HBV-associated PAN patients with an antiviral agent (vidarabine, interferon alfa, or <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, depending upon the era), a two-week course of glucocorticoids, and an intensive schedule of plasma exchange [<a href="#rid23">23</a>]. Their clinical course and outcomes were compared with 35 historic controls (before the antiviral era) treated with glucocorticoids with or without <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, with most receiving plasma exchange. The results indicated non-statistically significant clinical benefits:</p><p class="bulletIndent1"><span class="glyph">●</span>Remission was attained by 81 percent of all patients; patients who did not achieve remission died within a mean of 178 days. Overall five-year survival was 73 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At a median of 237 months, combination therapy with antivirals, immunosuppression, and plasmapheresis was associated with lower rates of relapse (4 versus 14 percent) and death (30 versus 49 percent), although the difference did not reach statistical significance.</p><p></p><p class="headingAnchor" id="H3089168161"><span class="h1">ISOLATED AND SINGLE-ORGAN PAN</span><span class="headingEndMark"> — </span>The approach to isolated or single-organ polyarteritis nodosa (PAN) depends upon the affected organ or tissue. Cutaneous PAN is generally treated similarly to mild systemic PAN (see <a class="local">'Isolated cutaneous PAN'</a> below), while isolated organ involvement, sometimes identified at the time of an operative procedure, may not require further therapy. (See <a class="local">'Isolated/single-organ PAN'</a> below.)</p><p class="headingAnchor" id="H1592963458"><span class="h2">Isolated cutaneous PAN</span><span class="headingEndMark"> — </span>The treatment for isolated cutaneous PAN varies depending on the severity of the cutaneous manifestations and associated symptoms. A detailed discussion on the diagnosis and treatment of cutaneous PAN is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/109628.html" rel="external">"Cutaneous polyarteritis nodosa"</a>.)</p><p>Patients with isolated cutaneous disease when first seen and initially treated may relapse with disease in other organs and should be monitored periodically as are other patients with mild disease. (See <a class="local">'Monitoring of disease'</a> below and  <a class="medical medical_review" href="/d/html/109628.html" rel="external">"Cutaneous polyarteritis nodosa", section on 'Follow-up'</a>.)</p><p class="headingAnchor" id="H1689100590"><span class="h2">Isolated/single-organ PAN</span><span class="headingEndMark"> — </span>Unlike cutaneous PAN, single-organ PAN is usually monophasic and does not relapse. The diagnosis of isolated single-organ PAN is typically made by histological examination of surgical specimens. Treatment beyond surgical excision is usually not necessary [<a href="#rid24">24</a>]. However, we fully evaluate such patients initially and provide regular clinical follow-up (every three months in the first year and every 6 to 12 months thereafter) to determine if additional anatomic areas or other clinical features are present or developing. (See  <a class="medical medical_review" href="/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a> and <a class="local">'Monitoring of disease'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h1">TREATMENT OF NONSEVERE PAN</span><span class="headingEndMark"> — </span>Patients with nonsevere disease, defined as not having organ- or life-threatening manifestations of polyarteritis nodosa (PAN), and without evidence of hepatitis, can be treated initially with glucocorticoids alone. However, because about half of these patients will require an additional agent at some point during their treatment, and given the substantial toxicities of glucocorticoids, we suggest additional immunosuppressive drug beyond glucocorticoids.</p><p>The treatment approach in patients with hepatitis B or C infection is discussed above. (See <a class="local">'Associated hepatitis B or C infection'</a> above.)</p><p class="headingAnchor" id="H3920038985"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>In patients with relatively mild disease, initial monotherapy with oral glucocorticoid may be reasonable, with dosing as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">Prednisone</a> 1 mg/kg daily (up to a maximum of 60 to 80 mg daily) for two to four weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Taper <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> to 20 mg daily by month 3 to 4</p><p class="bulletIndent1"><span class="glyph">●</span>Taper <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> in 2.5 mg increments every 14 days until glucocorticoids are discontinued</p><p></p><p>Patients should be monitored closely for evidence of disease relapse, which may require slowing of the <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> taper or the institution of an additional glucocorticoid-sparing agent. (See <a class="local">'Other immunosuppressive agents'</a> below.)</p><p>In patients with mild disease) who are resistant to or intolerant of the dose of glucocorticoids required for disease control, we suggest the addition of either <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (2 mg/kg daily) or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (20 to 25 mg once weekly) for at least one year. (See <a class="local">'Other immunosuppressive agents'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale - </strong>This approach is based upon the potential benefit of glucocorticoids alone seen in retrospective studies [<a href="#rid6">6-8</a>] and in patients with mild PAN and microscopic polyangiitis (MPA) in the nonrandomized initial phase of a randomized trial [<a href="#rid2">2</a>]. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective analysis of patients with PAN that was not limited to those with mild disease found that patients treated with glucocorticoids alone, when compared with clinically similar patients who did not receive glucocorticoids, experienced substantially longer median survival (63 versus 3 months) and five-year survival (53 versus 12 percent) [<a href="#rid8">8</a>]. Glucocorticoids have not been compared with treatment with placebo alone in a randomized trial.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized trial of patients with mild PAN or MPA designed to compare <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> in patients who had sustained disease or relapse despite glucocorticoid therapy, 79 percent of patients achieved remission with initial glucocorticoid therapy prior to the randomized trial period [<a href="#rid2">2</a>]; half of these patients had a sustained remission without requiring additional immunosuppression.</p><p></p><p class="bulletIndent1">Alternatively, some experts advocate longer treatment courses with glucocorticoids, especially if no other immunosuppressive agent is prescribed concurrently, but trials have not been performed to prospectively compare the long-term outcomes of different durations of therapy. Some patients may require a slower taper. Our approach is to steadily taper the dose of glucocorticoids for patients in remission and closely monitor the patient's condition, only resuming or raising the dose of glucocorticoids if there is evidence of recurrent active PAN.</p><p></p><p class="bulletIndent1">Those who respond to glucocorticoids alone are spared the risk of adverse effects associated with the use of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> or other immunosuppressive drugs. However, treatment with glucocorticoids may be associated with multiple adverse effects that, in many patients, may be more serious that the side effects of other immunosuppressive drugs. The risks of systemic glucocorticoids and prophylaxis for glucocorticoid-induced osteoporosis are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p></p><p class="headingAnchor" id="H2461834859"><span class="h2">Other immunosuppressive agents</span></p><p class="headingAnchor" id="H3094579938"><span class="h3">Indications</span><span class="headingEndMark"> — </span>Patients with mild disease who are resistant to or intolerant of glucocorticoids require additional or alternative treatment. In addition, because about half of patients with mild disease will require an additional agent at some point during their treatment, and given the substantial toxicities of glucocorticoids, we suggest treatment with an additional immunosuppressive drug beyond glucocorticoids for most patients with mild disease.</p><p class="headingAnchor" id="H122053743"><span class="h3">Methotrexate versus azathioprine</span><span class="headingEndMark"> — </span>When a decision is made to start an immunosuppressive drug in addition to glucocorticoids for treatment of nonsevere disease, our preference is for either <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (2 mg/kg daily) or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (20 to 25 mg once weekly) for at least one year. </p><p>We base the choice between <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> on an evaluation of potential contraindications, and patient and clinician preferences regarding dosing and administration of the drugs. Methotrexate may be faster-acting but should be avoided in patients with kidney disease or hepatitis. We thus prefer azathioprine in patients with kidney disease and in patients with hepatic disease, although these patients should be closely monitored for hepatotoxicity.</p><p>There is limited evidence to support this approach to treatment of nonsevere disease. In a small trial of 95 patients with a case mix of PAN, eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss), and MPA compared the addition of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or placebo to standard daily oral glucocorticoids for patients classified as having nonsevere disease [<a href="#rid25">25</a>]. The trial did not find a benefit of azathioprine in terms of rates of attaining remission, risk of relapse, or cumulative dose of glucocorticoids. However, only a minority, 19 out of 51 (37 percent) had PAN, limiting the interpretation of these results for patients with PAN. The small sample size of patients with PAN precluded disease-specific subset efficacy analysis. More data are needed on the efficacy of azathioprine and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> as "glucocorticoid-sparing" agents for patients with mild PAN to guide therapy.</p><p class="headingAnchor" id="H730888045"><span class="h3">Other agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role for </strong><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> – There are few randomized trials in patients with PAN that have directly compared the efficacy of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, cyclophosphamide, and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, but we generally avoid the use of cyclophosphamide in patients with nonsevere PAN. One small randomized trial has shown similar benefit but lower toxicity with azathioprine compared with cyclophosphamide in such patients [<a href="#rid2">2</a>]. In our clinical experience as well as in observational studies of PAN, cyclophosphamide appears to have greater toxicity compared with azathioprine or methotrexate; this was observed in trials of patients with other forms of systemic necrotizing vasculitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a><strong> mofetil</strong> – We also prefer to use either <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> over mycophenolate (2000 to 3000 mg daily) [<a href="#rid26">26-30</a>]. Mycophenolate has been shown to be less efficacious than azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Choice of maintenance therapy'</a>.)</p><p></p><p class="bulletIndent1">However, this approach is based on clinical experience and limited data from small trials [<a href="#rid2">2,31</a>], as well as from indirect evidence from the use of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> for maintenance of remission in ANCA-associated vasculitis. The role of alternative regimens for the treatment of moderate to severe PAN is not well-established, and there are minimal data to support their use. (See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Choice of maintenance therapy'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT OF SEVERE PAN</span><span class="headingEndMark"> — </span>Patients with disease that is organ- or life-threatening are often treated in two phases: a remission induction phase and a remission maintenance phase.</p><p class="headingAnchor" id="H1992904990"><span class="h2">Remission induction</span><span class="headingEndMark"> — </span>For patients with severe disease, we suggest initiating treatment with both <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (either oral or intravenous) and high-dose glucocorticoids.</p><p class="headingAnchor" id="H2751134961"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>We suggest pulse glucocorticoid therapy along with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> in patients with severe, active polyarteritis nodosa (PAN).</p><p>Intravenous <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> is dosed at 7 to 15 mg/kg to a maximum of 500 to 1000 mg administered intravenously once daily for three days. Afterwards, oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> should be administered at 1 mg/kg daily for two to four weeks and gradually tapered as described above. (See <a class="local">'Treatment of nonsevere PAN'</a> above.)</p><p>In our experience, pulse therapy provides more rapid control of disease. This approach is also supported by other experts, but there are no randomized trials comparing pulse with high-dose oral glucocorticoid therapy in patients with PAN [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H3663563727"><span class="h3">Cyclophosphamide</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> along with high-dose glucocorticoids for treatment of severe PAN. Support for the use of cyclophosphamide for remission-induction is indirect and is based upon expert experience and randomized trials using these medications in patients with other forms of necrotizing vasculitis. (See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a> and  <a class="medical medical_review" href="/d/html/4346.html" rel="external">"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Oral <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is dosed at 2 mg/kg daily for three to six months until remission is achieved. When intravenous cyclophosphamide is used, we suggest treatment with 15 mg/kg administered at weeks 0, 2, and 4, and then every three weeks [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">An alternative regimen is intravenous pulse therapy with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (600 mg/m<sup>2</sup>) every two weeks for three doses, in addition to the glucocorticoid regimen, then every four weeks for at least four months and until a stable remission has been achieved, but for no greater than six months.</p><p></p><p class="bulletIndent1">All the recommended doses of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, both by oral and intravenous routes, must be adjusted for kidney function, for age, and in response to possibly neutropenia or other hematologic toxicities. The use of cyclophosphamide, including monitoring and prevention of adverse effects, and strategies for dose adjustments are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral versus intravenous administration</strong> – In our experience, use of oral versus intravenous <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> results in a similar degree of benefit. While the comparative efficacy of treatment with oral and intravenous cyclophosphamide has been studied in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, similar comparisons in patients with PAN have not been performed [<a href="#rid33">33-35</a>].</p><p></p><p class="bulletIndent1">Theoretically, compared with oral therapy, intravenous therapy may be associated with lower cumulative dose and potentially reduced risk of bone marrow, bladder, ovarian, and testicular toxicity. However, given that current practice for the use of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> in vasculitis is to limit treatment with drug to four to six months, the route of administration is now less of deciding factor since the differences between potential toxicities between oral and intravenous administration are lessened with reduced exposure.</p><p></p><p class="bulletIndent1">Oral therapy with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is an alternative preferred by some patients for its convenience and by some experts because of the long experience with this approach in ANCA-associated vasculitis, such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of </strong><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a><strong> treatment</strong> – Based upon data in other forms of vasculitis and our experience, we generally avoid courses of cyclophosphamide longer than four months if remission has been achieved by that time.</p><p></p><p class="bulletIndent1">While one randomized trial of 65 patients with moderate to severe disease (18 patients had PAN; 47 had MPA) reported somewhat better outcomes with 12 versus 6 monthly pulses of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, only a minority of patients had PAN, and the study did not include a remission-maintenance regimen with an alternative immunosuppressive regimen [<a href="#rid36">36</a>]. Moreover, some toxicities of cyclophosphamide only become apparent several years after treatment (eg, premature ovarian failure or bladder cancer).</p><p></p><p class="headingAnchor" id="H3060261409"><span class="h2">Remission maintenance</span><span class="headingEndMark"> — </span>In patients who have completed a course of therapy with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, we switch to another immunosuppressive agent, such as <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (2 mg/kg daily) or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (20 to 25 mg once weekly) for a total duration of immunosuppressive therapy (including cyclophosphamide and the subsequent agent) of 18 months. Patients with relapsing disease may require longer courses of therapy.</p><p>We avoid the continued use of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> for remission maintenance due to its toxicity and prefer to use either <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> over <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> for this purpose [<a href="#rid26">26-30</a>].</p><p>The choice between <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> often depends on the potential for treatment-associated adverse events, dosing regimens, and both provider and patient preferences. Methotrexate is likely faster-acting but should be avoided in patients with kidney disease or hepatitis.</p><p>In patients with poor tolerance of, or contraindications to, both <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, we use <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (2000 to 3000 mg daily).</p><p>The highest tolerated dose of a given agent, up to the recommended maximum, should be used for several months before presuming it is insufficient and that another medication is required.</p><p>This approach is supported indirectly by randomized trials and experience in patients with ANCA-associated vasculitis, but there are no randomized trials or observational studies that have formally examined this approach or compared <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> in patients with PAN in this setting [<a href="#rid2">2</a>]. Nonetheless, use of this strategy in patients with PAN has been effective in our experience. The use of this approach in ANCA-associated vasculitis is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4346.html" rel="external">"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Maintenance therapy'</a>.)</p><p>The monitoring and potential adverse effects of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Maintenance therapy'</a>.)</p><p class="headingAnchor" id="H2801409476"><span class="h2">Resistant disease</span><span class="headingEndMark"> — </span>Infrequently, patients do not respond adequately to glucocorticoids and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> treatment. In patients with severe PAN who have ongoing severe or worsening disease that is not controlled by treatment with glucocorticoids and cyclophosphamide within two to three months, we treat with pulse glucocorticoids (eg, 1000 mg <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> administered intravenously daily for three days), followed by <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (1 mg/kg daily taken orally), and switch from cyclophosphamide to a different immunosuppressive agent.</p><p>We base the choice of alternative immunosuppressive agent on the patient's history of medication use and comorbidities. We usually prescribe an agent not previously used by the patient from among the following: <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>. (See <a class="local">'Other immunosuppressive agents'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternate biologic therapies</strong> – There has been increasing interest in the use of biologic drugs for the treatment of patients with relapsing or refractory PAN. A multicenter, retrospective case series examined 42 patients with PAN who received anti-tumor necrosis factor (TNF) drugs, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, or <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> after at least one initial course of treatment with glucocorticoids and, usually, another nonbiologic immunosuppressive agent [<a href="#rid37">37</a>]. Complete or partial responses were achieved for 53 percent for patients given anti-TNF drugs, 44 percent for patients given rituximab, and 80 percent for patients given tocilizumab. Almost all patients (95 percent) also received glucocorticoids with the biologic drug.</p><p></p><p class="bulletIndent1">Although this retrospective series is subject to possible biases in case identification and data collection, these data provide some support to smaller reports which describe treatment of PAN with anti-TNF alpha agents [<a href="#rid38">38</a>], <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid39">39</a>], and <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> [<a href="#rid37">37,40-48</a>]. This report suggests that it is reasonable to consider prescribing an anti-TNF drug or tocilizumab for patients with relapsing/refractory PAN. Although rituximab is also an option for the treatment of patients without hepatitis B virus (HBV) infection, the data from this case series and the long biological impact of rituximab and its effect on response to vaccination make it a less preferred alternative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternate non-biologic therapies</strong> – An extremely small number of case reports have been published describing treatment of PAN with <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a> [<a href="#rid49">49</a>] and <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> [<a href="#rid50">50</a>], but publication bias and other factors make interpretation and application of these results difficult.</p><p></p><p class="headingAnchor" id="H1147024"><span class="h2">Other management considerations</span></p><p class="headingAnchor" id="H1148344"><span class="h3">Hypertension</span><span class="headingEndMark"> — </span>Hypertension can be a major therapeutic issue in patients with PAN. The elevation in blood pressure may be severe and is often mediated by ischemia-induced activation of the renin-angiotensin system [<a href="#rid51">51</a>]. The intrarenal large vessel disease in PAN may, therefore, be the functional equivalent of extrarenal vascular disease in bilateral renal artery stenosis. The management of renovascular hypertension is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney", section on 'Medical therapy'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Pneumocystis jirovecii prophylaxis</span><span class="headingEndMark"> — </span>Prophylaxis for <em>Pneumocystis jirovecii</em> infection should be employed in patients being treated for PAN using the regimens associated with such risk in patients with GPA, such as a significant dose of glucocorticoids (eg, ≥20 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> daily for one month or longer) in combination with a second immunosuppressive drug, particularly a cytotoxic agent (eg, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>). (See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H12933842"><span class="h1">MONITORING OF DISEASE</span><span class="headingEndMark"> — </span>Patients with polyarteritis nodosa (PAN; including cutaneous and single-organ PAN) require regular, long-term follow-up to monitor the disease and drug safety by a clinician familiar with the disease and its treatments. Patients must be monitored for the possibility of disease relapse, particularly in organ systems involved at disease onset. However, patients with PAN may have relapses of disease that include clinical manifestations of vasculitis not present at diagnosis [<a href="#rid52">52</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency of monitoring</strong> – We generally see patients at least monthly during the initial phase of therapy until clinically stable, then at least every three months during the first two years of treatment. We continue to follow patients who have been in remission for two years every three to six months. Even after two years of remission, all patients should be followed indefinitely at some reasonable frequency (eg, every 6 to 12 months) since relapses may occur years after initial presentation and attainment of remission, which may be defined for patients with PAN as the absence of any evidence of active disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of monitoring</strong> – In addition to routine physical examinations, including blood pressure testing, a review of systems, and laboratory monitoring for drug toxicities, a serum creatinine and urinalysis should be obtained at each visit.</p><p></p><p class="bulletIndent1">New symptoms or findings should be evaluated for their potential to represent recurrent vasculitis, even if such symptoms or findings are different from the original presenting manifestations of disease. Additionally, patients must be followed and treated for the medium- and long-term clinical sequelae of both treatment toxicities and disease-related long-term organ damage. (See  <a class="medical medical_review" href="/d/html/8224.html" rel="external">"Overview of the management of vasculitis in adults", section on 'Monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of imaging</strong> – Follow-up angiography is not required unless there are signs or symptoms suggestive of new disease, concerns for ischemia that may require intervention, or aneurysms that are at risk for expansion or rupture and may require intervention. Depending on the anatomic location and size of affected arteries, magnetic resonance imaging (MRI) or computed tomographic (CT) angiography may be substituted for catheter-based angiography. The choice of which imaging modality (MR, CT, or catheter-based) to use will depend upon the availability of equipment and expertise at a medical center and may be influenced by an interest in utilizing the same approach used for prior evaluations to allow for direct comparisons.</p><p></p><p class="bulletIndent1">Serial angiograms may be required to differentiate active from inactive disease. Some complications of PAN can occur when the disease is clinically inactive, since healing of inflamed vessels can lead to progressive narrowing of the vascular lumina and resultant organ ischemia. Such changes should be distinguished from active disease, as they require appropriate supportive care rather than immunosuppression. As an example, a slowly progressive elevation in the serum creatinine concentration occurs in some patients in whom the signs of active vasculitis (such as systemic symptoms and an active urine sediment) have abated. The primary problem in this situation is diminished glomerular flow, not vascular inflammation.</p><p></p><p class="headingAnchor" id="H10269109"><span class="h1">RECURRENT DISEASE</span><span class="headingEndMark"> — </span>The treatment of recurrent disease depends upon the severity of the flare and whether recurrence occurs on or off immunosuppressive treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsevere relapse</strong> – Nonsevere disease relapse may be treated by use of glucocorticoids alone and/or by an increase in dose of immunosuppressive drug, depending upon the patient's treatment at the time of disease exacerbation or recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe relapse</strong> – Severe relapse requires reinitiation of remission-induction treatment (see <a class="local">'Other management considerations'</a> above). If moderate to severe recurrence occurs when the patient is on immunosuppressive treatment, a different immunosuppressive agent should be used. (See <a class="local">'Resistant disease'</a> above.)</p><p></p><p>Patients with relapsing disease may benefit from longer courses of therapy. Some patients may also benefit from the addition of low-dose glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> ≤10 mg daily) for maintenance of remission when mild symptoms of PAN recur off glucocorticoids (eg, arthralgias, fatigue, or skin lesions).</p><p class="headingAnchor" id="H12"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H12933849"><span class="h2">Morbidity and mortality</span><span class="headingEndMark"> — </span>Untreated polyarteritis nodosa (PAN) is associated with a poor prognosis (13 percent five-year survival) [<a href="#rid5">5,6</a>]. The outcome of PAN has improved in patients receiving treatment; five-year survival is approximately 80 percent [<a href="#rid7">7</a>]. The survival rates for patients with hepatitis B virus (HBV)-associated PAN are lower than for patients with non-HBV-associated disease. In one large cohort, the one- and five-year survival rates were substantially higher among patients diagnosed after 1995 compared with prior to 1995, possibly indicative of more rapid and widespread use of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> for more severe disease [<a href="#rid7">7</a>]. Whether prognosis of HBV-associated PAN has improved with the introduction of newer antiviral treatments is not known. Most deaths in patients with PAN due to active disease occur within 18 months of disease onset [<a href="#rid4">4,7</a>]. Survival is better among those with limited organ involvement.</p><p>Kidney failure and mesenteric, cardiac, or cerebral infarction are the major causes of death. Some of these complications can occur at a time when the disease is clinically inactive, since healing of inflamed vessels can lead to progressive narrowing of the vascular lumina and resultant organ ischemia. Preservation of tissue function is most likely if treatment is instituted early in the course of the disease.</p><p>Improvement in kidney function may be seen even in patients who initially require dialysis. In this setting, sufficient recovery to allow the patient to be maintained off dialysis for one to two years or more occurs in up to 60 percent of cases [<a href="#rid53">53</a>] and in approximately 10 percent who undergo dialysis for as long as three to six months [<a href="#rid54">54</a>].</p><p>In order to better define prognostic factors in PAN, the French Vasculitis Study Group established a large, well-characterized longitudinal cohort of patients with PAN and reported a comprehensive series of studies on the natural history and treatment of this disorder [<a href="#rid7">7</a>]. Using regression analytic techniques, this group derived the "Five-Factor Score" (FFS) in 1996 as a simple prognostic tool for clinicians to use when evaluating patients with various forms of vasculitis, including PAN [<a href="#rid4">4,13,55</a>]. The FFS was revised in 2011 based upon additional data and for PAN now only includes four factors associated with increased mortality: age &gt;65 years, cardiac symptoms, gastrointestinal involvement, and kidney insufficiency (plasma creatinine &gt;1.7 mg/dL [150 micromol/L]) [<a href="#rid13">13</a>]. The original FFS included central nervous system disease (dropped from the score in 2011) but did not include age (included in 2011). The FFS has been used to stratify patients in treatment studies; this tool is helpful in both interpreting the data and formulating an approach to treatment of PAN. However, the FFS is based upon mortality and is not designed to predict either relapse or long-term morbidity, both of which are also important outcomes that influence treatment decisions in PAN.</p><p class="headingAnchor" id="H1147049"><span class="h2">Relapse rates</span><span class="headingEndMark"> — </span>Although the proportion of patients with PAN with monocyclic disease courses (ie, a single episode of disease activity without a subsequent relapse) is substantially higher than in many other forms of vasculitis, especially the antineutrophil cytoplasmic antibody (ANCA)-associated diseases (granulomatosis with polyangiitis [GPA], microscopic polyangiitis [MPA], and eosinophilic granulomatosis with polyangiitis [EGPA; Churg-Strauss]), the relapse rate in PAN is still substantial. For example, in a series of 348 patients, the one- and five-year relapse rates for patients with non-HBV-associated PAN were at least 9.2 percent and 24 percent, respectively; the relapse rates for HBV-associated PAN were lower [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Kidney transplantation</span><span class="headingEndMark"> — </span>Few data exist concerning the outcome of patients with PAN and end-stage kidney disease who undergo kidney transplantation. Among 112 patients with PAN reported in the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) registry, transplantation was associated with significantly lower patient (77 versus 91 percent) and first cadaveric allograft (60 versus 69 percent) survival rates compared with those diagnosed with other kidney diseases (eg, glomerulonephritis, interstitial nephritis, toxic nephropathies, and cystic kidney disease) [<a href="#rid56">56</a>]. Thirteen percent of graft failures were reportedly due to recurrent disease.</p><p class="headingAnchor" id="H2579078238"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110743.html" rel="external">"Society guideline links: Vasculitis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/121058.html" rel="external">"Society guideline links: Polyarteritis nodosa"</a>.)</p><p class="headingAnchor" id="H28413256"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83628.html" rel="external">"Patient education: Polyarteritis nodosa (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial assessment</strong> – Prior to initiating pharmacotherapy, patients should undergo a thorough clinical evaluation to determine the extent and severity of polyarteritis nodosa (PAN)-associated organ involvement, which may influence the choice of pharmacotherapy. Patients should also undergo serologic testing for viral hepatitis. If prescribed, <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> should be stopped, since it can be associated with PAN. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral hepatitis-associated disease</strong> – In patients with mild PAN and evidence of infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), we suggest initial with antivirals only, rather than also treating initially with immunosuppressive medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Associated hepatitis B or C infection'</a> above.)</p><p></p><p class="bulletIndent1">Some patients with severe manifestations of hepatitis virus-associated PAN may benefit from short-term treatment with glucocorticoids or plasma exchange until antiviral therapy becomes effective.</p><p></p><p class="bulletIndent1">In patients with persistent manifestations of PAN who are unresponsive to or intolerant of treatment for viral hepatitis alone, we cautiously treat the manifestations of the vasculitis with glucocorticoids and other immunosuppressive medication depending upon the severity of the vasculitis. (See <a class="local">'Treatment of nonsevere PAN'</a> above and <a class="local">'Treatment of severe PAN'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolated disease</strong> – PAN affecting a single organ may be discovered following surgical excision of an involved organ. If the PAN is isolated to the excised tissue, immunosuppressive therapy may not be required, although such patients should be monitored clinically for evidence of disease recurrence or progression. (See <a class="local">'Isolated/single-organ PAN'</a> above.)</p><p></p><p class="bulletIndent1">PAN isolated to the skin is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/109628.html" rel="external">"Cutaneous polyarteritis nodosa"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsevere PAN</strong> – In patients with nonsevere PAN disease (eg, absence of life- or organ-threatening disease manifestations), we suggest treatment with both glucocorticoids and a steroid-sparing agent rather than glucocorticoids alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoids</strong> – In most patients, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is administered orally (1 mg/kg daily to a maximum of 60 to 80 mg daily). The initial oral prednisone dose is continued for two to four weeks, until significant improvement is observed. The dose should then be tapered slowly, for an overall course of approximately six to eight months. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Steroid-sparing agent</strong> – We will typically use <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (2 mg/kg daily), <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (20 to 25 mg once weekly) or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (2 to 3 g daily), for a total duration of immunosuppressive therapy of 24 months. (See <a class="local">'Treatment of nonsevere PAN'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe disease</strong> – In a patient with severe disease (eg, ulcerative or gangrenous lesions of the extremities, acute kidney injury, polyneuropathy, central nervous system involvement, mesenteric arteritis, or myocardial ischemia), we recommend treatment with both glucocorticoids and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> rather than glucocorticoids alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Treatment of severe PAN'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoids</strong> – In patients with severe, life-threatening manifestations or worsening mononeuritis multiplex, we usually administer intravenous <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> initially (7 to 15 mg/kg to a maximum of 500 to 1000 mg administered intravenously once daily for three days) prior to initiating therapy with oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> – Cyclophosphamide may be administered by either intravenous or oral administration. We prefer the use of intravenous pulse therapy with cyclophosphamide 15 mg/kg administered at weeks 0, 2, and 4, and then every three weeks for at least four months and until a stable remission has been achieved, but for no greater than six months. (See <a class="local">'Cyclophosphamide'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Remission maintenance</strong> – In patients treated with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, we suggest a maintenance regimen with another immunosuppressive agent, such as <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (2 mg/kg daily) or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (20 to 25 mg once weekly) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), for a total duration of immunosuppressive therapy of 18 months. (See <a class="local">'Remission maintenance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistant disease</strong> – In the infrequent patient with moderate to severe PAN who has ongoing severe or worsening disease that is not controlled by treatment with glucocorticoids and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> within two to three months, we treat with pulse glucocorticoids (eg, 1000 mg <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> administered intravenously daily for three days), followed by <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (1 mg/kg daily taken orally), and switch from cyclophosphamide to a different immunosuppressive agent. Alternatives in patients unresponsive to or intolerant of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> are <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (2000 to 3000 mg daily), tumor necrosis factor (TNF) inhibitors, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, and <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>. (See <a class="local">'Resistant disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other management considerations</strong> – Patients with PAN may develop renovascular hypertension. (See  <a class="medical medical_review" href="/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney", section on 'Medical therapy'</a>.)</p><p></p><p class="bulletIndent1">Prophylaxis against <em>Pneumocystis jirovecii</em> should also be considered in patients treated with immunosuppressive agents. (See <a class="local">'Other management considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease monitoring</strong> – We suggest close follow-up of patients to monitor for disease relapse and for drug toxicities. Disease relapses may include new findings that were not part of the patient’s initial presentation. Angiography is not required unless there are findings suggestive of new disease. (See <a class="local">'Monitoring of disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent disease</strong> – Nonsevere disease recurrence may be treated with glucocorticoids alone and/or an increase in dose of the immunosuppressive drugs.</p><p></p><p class="bulletIndent1">Severe disease relapse requires reinitiation of the remission induction therapy. Patients with relapsing disease may benefit from the long-term use of low-dose glucocorticoids (See <a class="local">'Resistant disease'</a> above and <a class="local">'Remission induction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Treated PAN is associated with a five-year survival of 80 percent. Older age, kidney failure, and mesenteric and cardiac infarctions are all associated with an increase in mortality.</p><p></p><p class="bulletIndent1">Most patients will never relapse. Kidney transplantation is associated with worse patient and allograft survival rates compared with patients with other diagnoses (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.</a></li><li><a class="nounderline abstract_t">Ribi C, Cohen P, Pagnoux C, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 2010; 62:1186.</a></li><li><a class="nounderline abstract_t">Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666.</a></li><li><a class="nounderline abstract_t">Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005; 84:323.</a></li><li><a class="nounderline abstract_t">Balow JE. Renal vasculitis. Kidney Int 1985; 27:954.</a></li><li><a class="nounderline abstract_t">Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med 1967; 43:8.</a></li><li><a class="nounderline abstract_t">Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010; 62:616.</a></li><li><a class="nounderline abstract_t">Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979; 67:941.</a></li><li><a class="nounderline abstract_t">Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301:235.</a></li><li><a class="nounderline abstract_t">Chung SA, Gorelik M, Langford CA, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Care Res (Hoboken) 2021; 73:1061.</a></li><li><a class="nounderline abstract_t">Chung SA, Gorelik M, Langford CA, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Rheumatol 2021; 73:1384.</a></li><li><a class="nounderline abstract_t">Kermani TA, Ham EK, Camilleri MJ, Warrington KJ. Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series. Semin Arthritis Rheum 2012; 42:213.</a></li><li><a class="nounderline abstract_t">Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90:19.</a></li><li><a class="nounderline abstract_t">Guillevin L, Mahr A, Cohen P, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004; 51:482.</a></li><li><a class="nounderline abstract_t">Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74:238.</a></li><li><a class="nounderline abstract_t">Guillevin L, Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial 2003; 7:155.</a></li><li><a class="nounderline abstract_t">Kruger M, Böker KH, Zeidler H, Manns MP. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol 1997; 26:935.</a></li><li><a class="nounderline abstract_t">Wicki J, Olivieri J, Pizzolato G, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford) 1999; 38:183.</a></li><li><a class="nounderline abstract_t">Avşar E, Savaş B, Tözün N, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy. J Hepatol 1998; 28:525.</a></li><li><a class="nounderline abstract_t">Simsek H, Telatar H. Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone. J Clin Gastroenterol 1995; 20:263.</a></li><li><a class="nounderline abstract_t">Guillevin L, Lhote F, Sauvaget F, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53:334.</a></li><li><a class="nounderline abstract_t">Janssen HL, van Zonneveld M, van Nunen AB, et al. Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gastroenterol Hepatol 2004; 16:801.</a></li><li><a class="nounderline abstract_t">Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84:313.</a></li><li><a class="nounderline abstract_t">Hernández-Rodríguez J, Hoffman GS. Updating single-organ vasculitis. Curr Opin Rheumatol 2012; 24:38.</a></li><li><a class="nounderline abstract_t">Puéchal X, Pagnoux C, Baron G, et al. Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial. Arthritis Rheumatol 2017; 69:2175.</a></li><li><a class="nounderline abstract_t">Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.</a></li><li><a class="nounderline abstract_t">De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461.</a></li><li><a class="nounderline abstract_t">Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351.</a></li><li><a class="nounderline abstract_t">Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359:2790.</a></li><li><a class="nounderline abstract_t">Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304:2381.</a></li><li><a class="nounderline abstract_t">Brogan PA, Arch B, Hickey H, et al. Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial. Arthritis Rheumatol 2021; 73:1673.</a></li><li><a class="nounderline abstract_t">Guillevin L, Pagnoux C. When should immunosuppressants be prescribed to treat systemic vasculitides? Intern Med 2003; 42:313.</a></li><li><a class="nounderline abstract_t">de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150:670.</a></li><li><a class="nounderline abstract_t">Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71:955.</a></li><li><a class="nounderline abstract_t">de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16:2018.</a></li><li><a class="nounderline abstract_t">Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003; 49:93.</a></li><li><a class="nounderline abstract_t">Hadjadj J, Canzian A, Karadag O, et al. Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study. Rheumatology (Oxford) 2022; 62:341.</a></li><li><a class="nounderline abstract_t">Ginsberg S, Rosner I, Slobodin G, et al. Infliximab for the treatment of refractory polyarteritis nodosa. Clin Rheumatol 2019; 38:2825.</a></li><li><a class="nounderline abstract_t">Seri Y, Shoda H, Hanata N, et al. A case of refractory polyarteritis nodosa successfully treated with rituximab. Mod Rheumatol 2017; 27:696.</a></li><li><a class="nounderline abstract_t">Boistault M, Lopez Corbeto M, Quartier P, et al. A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report. Pediatr Rheumatol Online J 2021; 19:168.</a></li><li><a class="nounderline abstract_t">Inoue N, Shimizu M, Mizuta M, Yachie A. Successful treatment of tumor necrosis factor inhibitor-resistant cutaneous polyarteritis nodosa with tocilizumab. Pediatr Int 2020; 62:753.</a></li><li><a class="nounderline abstract_t">Watanabe K, Rajderkar DA, Modica RF. A Case of Polyarteritis Nodosa Associated with Vertebral Artery Vasculitis Treated Successfully with Tocilizumab and Cyclophosphamide. Case Rep Pediatr 2016; 2016:7987081.</a></li><li><a class="nounderline abstract_t">Krusche M, Ruffer N, Schneider U, et al. Tocilizumab treatment for polyarteritis nodosa. Rheumatology (Oxford) 2020; 59:e63.</a></li><li><a class="nounderline abstract_t">Saunier A, Issa N, Vandenhende MA, et al. Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach? RMD Open 2017; 3:e000446.</a></li><li><a class="nounderline abstract_t">Hočevar A, Lestan B, Šemrl SS, et al. AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab. Amyloid 2013; 20:275.</a></li><li><a class="nounderline abstract_t">Krusche M, Ruffer N, Kötter I. Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature. Rheumatol Int 2019; 39:337.</a></li><li><a class="nounderline abstract_t">Bodoki L, Végh E, Szekanecz Z, Szűcs G. Tocilizumab Treatment in Polyarteritis Nodosa. Isr Med Assoc J 2019; 21:560.</a></li><li><a class="nounderline abstract_t">Carrión-Barberà I, Pros A, Salman-Monte TC, et al. Safe and successful treatment of refractory polyarteritis nodosa with tocilizumab in a patient with past hepatitis B virus infection: a case-based review. Clin Rheumatol 2021; 40:2065.</a></li><li><a class="nounderline abstract_t">Mustapha N, Barra L, Carette S, et al. Efficacy of leflunomide in the treatment of vasculitis. Clin Exp Rheumatol 2021; 39 Suppl 129:114.</a></li><li><a class="nounderline abstract_t">Rimar D, Alpert A, Starosvetsky E, et al. Tofacitinib for polyarteritis nodosa: a tailored therapy. Ann Rheum Dis 2016; 75:2214.</a></li><li><a class="nounderline abstract_t">Stockigt JR, Topliss DJ, Hewett MJ. High-renin hypertension in necrotizing vasculitis. N Engl J Med 1979; 300:1218.</a></li><li><a class="nounderline abstract_t">Grayson PC, Cuthbertson D, Carette S, et al. New features of disease after diagnosis in 6 forms of systemic vasculitis. J Rheumatol 2013; 40:1905.</a></li><li><a class="nounderline abstract_t">Hind CR, Paraskevakou H, Lockwood CM, et al. Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet 1983; 1:263.</a></li><li><a class="nounderline abstract_t">Nissenson AR, Port FK. Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders. Q J Med 1990; 74:63.</a></li><li><a class="nounderline abstract_t">Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17.</a></li><li><a class="nounderline abstract_t">Briggs JD, Jones E. Renal transplantation for uncommon diseases. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. Nephrol Dial Transplant 1999; 14:570.</a></li></ol></div><div id="topicVersionRevision">Topic 8244 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23045170" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20131268" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263782" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148732" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2862306" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Renal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4157287" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Long-term follow-up study of periarteritis nodosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20112401" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/42314" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Immunosuppressive and corticosteroid therapy of polyarteritis nodosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36563" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cyclophosphamide therapy of severe systemic necrotizing vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34235889" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34235883" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704357" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21200183" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188337" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7565065" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12918937" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Indications of plasma exchanges for systemic vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9126810" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10342635" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551696" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797845" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7912504" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15256984" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148731" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22089096" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Updating single-organ vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28678392" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12840090" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16052573" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15673801" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Etanercept plus standard therapy for Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109574" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21060104" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33760371" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12729318" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : When should immunosuppressants be prescribed to treat systemic vasculitides?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451574" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22128076" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11572891" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12579599" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35686919" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30972576" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Infliximab for the treatment of refractory polyarteritis nodosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671401" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A case of refractory polyarteritis nodosa successfully treated with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34861842" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32515121" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Successful treatment of tumor necrosis factor inhibitor-resistant cutaneous polyarteritis nodosa with tocilizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27018080" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A Case of Polyarteritis Nodosa Associated with Vertebral Artery Vasculitis Treated Successfully with Tocilizumab and Cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32182367" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Tocilizumab treatment for polyarteritis nodosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28879047" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24106820" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30465270" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31474022" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tocilizumab Treatment in Polyarteritis Nodosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32833086" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Safe and successful treatment of refractory polyarteritis nodosa with tocilizumab in a patient with past hepatitis B virus infection: a case-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33200732" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy of leflunomide in the treatment of vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27558986" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Tofacitinib for polyarteritis nodosa: a tailored therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34795" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : High-renin hypertension in necrotizing vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23908447" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : New features of disease after diagnosis in 6 forms of systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6130293" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1970184" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8569467" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10193801" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Renal transplantation for uncommon diseases. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
